Syntagon Restructures

Syntagon will implement a restructuring program designed to improve its offering to customers in the field of drug substance development.

The company’s Sweden-based operations, Syntagon AB, will focus and strengthen its customer-oriented expertise within drug substance development, quality assurance and regulatory support, while the Latvian site, SIA Syntagon Baltic, will ramp up capacity and know-how within the field of preclinical and clinical deliveries of drug substances. The moves will result in the relocation of several positions from Syntagon’s Sweden base, south of the Swedish capital Stockholm, to the company’s Latvian site.

“The reorganization will enable Syntagon to build more dedicated core competence areas, while maintaining the high quality of service Syntagon has been delivering to its customers worldwide for the past 13 years,” says Syntagon’s chief executive officer, Andis Slaitas.